TRDA Entrada Therapeutics Inc

Price (delayed)

$6.5

Market cap

$253.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.96

Enterprise value

$199.06M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 24
Highlights
TRDA's debt is down by 11% YoY and by 2.4% from the previous quarter
TRDA's net income has shrunk by 126% YoY
TRDA's EPS has plunged by 115% YoY

Key stats

What are the main financial stats of TRDA

TRDA stock price

How has the Entrada Therapeutics stock price performed over time
Intraday
-3.13%
1 week
-5.66%
1 month
-14.13%
1 year
27.7%
YTD
-36.77%
QTD
-11.68%

Financial performance

How have Entrada Therapeutics's revenue and profit performed over time
Revenue
$4.69M
Gross profit
$4.69M
Operating income
-$176.53M
Net income
-$165.78M
Gross margin
100%
Net margin
-3,537.7%
TRDA's net income has shrunk by 126% YoY
Entrada Therapeutics's revenue has plunged by 94% YoY and by 18% from the previous quarter
The gross profit has dropped by 94% year-on-year and by 18% since the previous quarter
The operating income has dropped by 84% year-on-year

Price vs fundamentals

How does TRDA's price correlate with its fundamentals

Growth

What is Entrada Therapeutics's growth rate over time

Valuation

What is Entrada Therapeutics stock price valuation
P/E
N/A
P/B
1.08
P/S
58.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
42.48
TRDA's EPS has plunged by 115% YoY
The equity has contracted by 38% YoY and by 14% from the previous quarter
TRDA's price to book (P/B) is 25% lower than its 5-year quarterly average of 1.5 and 7% lower than its last 4 quarters average of 1.2
Entrada Therapeutics's revenue has plunged by 94% YoY and by 18% from the previous quarter
The stock's P/S is 35% more than its last 4 quarters average of 44.7

Efficiency

How efficient is Entrada Therapeutics business performance
TRDA's ROS is down by 22% from the previous quarter
The ROIC has declined by 16% since the previous quarter
Entrada Therapeutics's return on equity has decreased by 13% QoQ
Entrada Therapeutics's return on assets has decreased by 10% QoQ

Dividends

What is TRDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TRDA.

Financial health

How did Entrada Therapeutics financials performed over time
Entrada Therapeutics's current ratio has decreased by 42% YoY and by 22% QoQ
TRDA's quick ratio is down by 41% year-on-year and by 21% since the previous quarter
TRDA's debt is 79% less than its equity
Entrada Therapeutics's debt to equity has soared by 50% YoY and by 17% from the previous quarter
The equity has contracted by 38% YoY and by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.